Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Cost of Revenue came in at $23.6 million in Q2 2026, up 26.71% YoY from $18.6 million in Q2 2025, and up 13.35% on a QoQ basis from $20.8 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 6 years of Cost of Revenue data on file, last reported at $23.6 million in Q2 2026.
- Quarterly Cost of Revenue rose 26.71% year-over-year to $23.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $85.6 million (up 14.9% YoY) and the FY2025 annual result came in at $77.7 million, up 27.52% from the prior year.
- Cost of Revenue rose to $23.6 million in Q2 2026, from $20.8 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $23.6 million in Q2 2026 to a low of $491000.0 in Q1 2023.
- A 5-year average of $12.9 million and a median of $11.5 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue sank 88.36% — and 2024, when it soared 2055.4%.
- Tracing KNSA's Cost of Revenue over 5 years: stood at $6.7 million in 2022, then surged by 42.83% to $9.6 million in 2023, then jumped by 86.73% to $17.9 million in 2024, then grew by 17.04% to $20.9 million in 2025, then advanced by 12.54% to $23.6 million in 2026.
- The last three Cost of Revenue figures came in at $23.6 million (Q2 2026), $20.8 million (Q1 2026), and $20.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn | 23.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.57 Mn |
| Jun 30, 2026 | 23.57 Mn |
| Mar 31, 2026 | 20.80 Mn |
| Mar 31, 2026 | 20.80 Mn |
| Dec 31, 2025 | 20.95 Mn |
| Dec 31, 2025 | 20.95 Mn |
| Sep 30, 2025 | 20.26 Mn |
| Sep 30, 2025 | 20.26 Mn |
| Jun 30, 2025 | 18.60 Mn |
| Jun 30, 2025 | 18.60 Mn |
| Mar 31, 2025 | 17.87 Mn |
| Mar 31, 2025 | 17.87 Mn |
| Dec 31, 2024 | 17.90 Mn |
| Dec 31, 2024 | 17.90 Mn |
| Sep 30, 2024 | 20.11 Mn |
| Sep 30, 2024 | 20.11 Mn |
| Jun 30, 2024 | 12.32 Mn |
| Jun 30, 2024 | 12.32 Mn |
| Mar 31, 2024 | 10.58 Mn |
| Mar 31, 2024 | 10.58 Mn |